Results 251 to 260 of about 288,727 (306)

AND‐Logic‐Gated Aptamer Switch for Precise Targeting and Regulation of RNA G‐Quadruplexes

Angewandte Chemie, EarlyView.
An AND‐logic‐gated aptamer switch enables tumor‐selective activation of RNA G‐quadruplex (rG4)‐targeting function. By combining cell‐surface recognition and intracellular redox sensing, the system achieves precise regulation of disease‐relevant RNA structures exclusively in tumor cells, with minimal off‐target effects in normal cells, offering a ...
Dan Wang, Ying Feng, Chun Kit Kwok
wiley   +1 more source

Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries. [PDF]

Life (Basel)
Ammendolia I, Mannucci C, Esposito E, Calapai G, Currò M, Midiri P, Mondello C, Cancellieri A, Cardia L, Calapai F.   +9 more
europepmc   +1 more source

Supplementary Figure S7 from Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in <i>EGFR</i> Mutation–positive Lung Cancer

Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masatsugu Hamaji, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai   +15 more
openalex   +1 more source

Tyrosine kinase inhibitors in Ewing's sarcoma: a systematic review. [PDF]

BMC Cancer
Assi A, Farhat M, Mohanna R, Hachem MCR, Zalaquett Z, Aoun M, Farraj SA, Daher M, Sebaaly A, Kourie HR.   +9 more
europepmc   +1 more source

Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias. [PDF]

Cureus
Alekrish Y, Alotaibi S, Iqbal Z, Aleem A.   +3 more
europepmc   +1 more source

Role of Tyrosine Kinase Inhibitors in Modulating Chondrocyte Activity and Cartilage Diseases. [PDF]

J Bone Metab
Hadid KA, Zaki MK, Alassaf FA, Abed MN.
europepmc   +1 more source

Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. [PDF]

Hypertension
Ky B, Liu T, Margulies KB, Mitchell JD, Haas NB, Gareen IF, Thangarajah M, Sicks JD, Domenico C, Narayan VK, Smith AM, Wilcox NS, Mittal K, Rhee JW, Armenian SH, Saphner T, Paul AK, Gartrell BA, Zaha VG, Anari F, Wong RL, Townsend RR, Wagner LI.   +22 more
europepmc   +1 more source

Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.

Oncology
Gameil A, Ghasoub R, Jafari N, Shafei L, Benkhadra M, Laws S, Hamad A, Sabet I, Milojkovic D, Fernyhough L.   +9 more
europepmc   +1 more source

Correction to "Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer". [PDF]

Mol Oncol
europepmc   +1 more source

Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy

雄登 松下, Yuto Matsushita, Takahiro Kojima, Takahiro OSAWA, Tomokazu Sazuka, Shingo Hatakeyama, Keisuke GOTO, Kazuyuki Numakura, Kazutoshi Yamana, Shuya Kandori, Kazutoshi Fujita, Kosuke Ueda, Hajime Tanaka, Ryotaro Tomida, Toshifumi Kurahashi, Yukari Bando, Naotaka Nishiyama, Takahiro Kimura, Shimpei Yamashita, Hiroshi Kitamura, Hideaki Miyake   +20 more
openalex   +1 more source